Literature DB >> 16902913

Relationship between point gene mutation, chromosomal abnormality, and tumour suppressor gene methylation status in colorectal adenomas.

H Judson1, A Stewart, A Leslie, N R Pratt, D U Baty, R J C Steele, F A Carey.   

Abstract

Epigenetic mechanisms in carcinogenesis may have a significant role in the development of colorectal cancer. To investigate this phenomenon in early-stage disease, promoter methylation status in the tumour suppressor genes APC, MGMT, hMLH1, P14/P14ARF, and CDKN2A/P16 was investigated in 78 colorectal adenomas. These had previously been characterized for mutations of APC, KRAS, and TP53 genes and for chromosomal abnormality by comparative genomic hybridization (CGH). APC hypermethylation was seen in 52 tumours (66.7%). APC showed either methylation or mutation in 66 lesions (84.6%), but these events were not statistically associated. MGMT methylation was detected in 39 cases (50%). Adenomas with this abnormality showed a significantly lower number of chromosomal changes by CGH (p < 0.02), confirming that DNA repair defect of this type is associated with a lower level of chromosomal instability. An hMLH1 methylation defect was seen in only one adenoma (1.3%), from a patient who had a synchronous cancer showing the same defect. Methylation of P14 (P14ARF) was seen in 31 adenomas (39.7%) and CDKN2A (P16) abnormality in 25 (32.1%). DNA methylation at two or more loci was seen in 46 tumours (59%), while 11 lesions (14.1%) showed no evidence of hypermethylation at any of the loci studied. Methylation at any or all of MGMT, P14 or P16 was significantly associated with APC methylation (p = 0.01). Those neoplasms with more than two methylated genes showed significantly fewer chromosomal abnormalities than adenomas with one or no methylated loci (p < 0.001). There was no association between specific individual chromosomal abnormalities, APC, KRAS or TP53 mutations and any pattern of methylation abnormality. We conclude that methylation abnormality is very common in pre-invasive colorectal neoplasia, and that high level methylation is associated with low level chromosomal instability. Copyright 2006 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16902913     DOI: 10.1002/path.2044

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  8 in total

1.  Aberrant DNA methylation of WNT pathway genes in the development and progression of CIMP-negative colorectal cancer.

Authors:  Orsolya Galamb; Alexandra Kalmár; Bálint Péterfia; István Csabai; András Bodor; Dezső Ribli; Tibor Krenács; Árpád V Patai; Barnabás Wichmann; Barbara Kinga Barták; Kinga Tóth; Gábor Valcz; Sándor Spisák; Zsolt Tulassay; Béla Molnár
Journal:  Epigenetics       Date:  2016-05-31       Impact factor: 4.528

2.  MTG16 is a tumor suppressor in colitis-associated carcinoma.

Authors:  Elizabeth M McDonough; Caitlyn W Barrett; Bobak Parang; Mukul K Mittal; J Joshua Smith; Amber M Bradley; Yash A Choksi; Lori A Coburn; Sarah P Short; Joshua J Thompson; Baolin Zhang; Shenika V Poindexter; Melissa A Fischer; Xi Chen; Jiang Li; Frank L Revetta; Rishi Naik; M Kay Washington; Michael J Rosen; Scott W Hiebert; Keith T Wilson; Christopher S Williams
Journal:  JCI Insight       Date:  2017-08-17

Review 3.  Genome-wide epigenetic modifications in cancer.

Authors:  Yoon Jung Park; Rainer Claus; Dieter Weichenhan; Christoph Plass
Journal:  Prog Drug Res       Date:  2011

Review 4.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

5.  Inactivation of promoter 1B of APC causes partial gene silencing: evidence for a significant role of the promoter in regulation and causative of familial adenomatous polyposis.

Authors:  A Rohlin; Y Engwall; K Fritzell; K Göransson; A Bergsten; Z Einbeigi; M Nilbert; P Karlsson; J Björk; M Nordling
Journal:  Oncogene       Date:  2011-06-06       Impact factor: 9.867

6.  Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations.

Authors:  Béla Molnár; Orsolya Galamb; Bálint Péterfia; Barnabás Wichmann; István Csabai; András Bodor; Alexandra Kalmár; Krisztina Andrea Szigeti; Barbara Kinga Barták; Zsófia Brigitta Nagy; Gábor Valcz; Árpád V Patai; Péter Igaz; Zsolt Tulassay
Journal:  BMC Cancer       Date:  2018-06-27       Impact factor: 4.430

7.  Prediction of the Prognosis Based on Chromosomal Instability-Related DNA Methylation Patterns of ELOVL2 and UBAC2 in PTCs.

Authors:  Jun Han; Meijun Chen; Qingxiao Fang; Yanqing Zhang; Yihan Wang; Jamaspishvili Esma; Hong Qiao
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-07       Impact factor: 8.886

Review 8.  The context and potential of epigenetics in oncology.

Authors:  J Lopez; M Percharde; H M Coley; A Webb; T Crook
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.